SinoMab FY26 H1 loss widens to RMB 127.4 million; funding available drops to RMB 196.5 millionPUBT·Aug 31 at 02:25 PM03681+0.88%
Strategy on the Periphery: Navigating Paradigm Shifts in Hong Kong EquitiesGlobal Report·Aug 25 at 11:32 AM03681+0.88%01712-7.19%
Biotech Ambitions and Travel Takeovers: Moves Reshaping Hong Kong's Mixed EquitiesGlobal Report·Aug 25 at 09:20 AM03692+0.78%03681+0.88%
SinoMab Seeks Shareholder Approval to Sell Suzhou Industrial Property for RMB280 MillionTip Ranks·Aug 20 at 10:37 PM03681+0.88%
SinoMab BioScience schedules board meeting to review interim resultsPUBT·Aug 19 at 11:04 AM03681+0.88%
SinoMab BioScience sets Sept. 7 shareholder vote on proposed Suzhou property, facility salePUBT·Aug 18 at 01:05 PM03681+0.88%
SinoMab BioScience files list of directors, board committee memberships and disclosure-responsible managementPUBT·Aug 18 at 10:45 AM03681+0.88%
The Misfit Toys of Hong Kong Equities: Who is Actually Working and Who is Faking ItGlobal Report·Aug 13 at 09:43 AM02005-0.18%015460.00%
SinoMab BioScience to sell Suzhou property, facility for RMB 280 millionPUBT·Jul 6 at 11:19 AM03681+0.88%
SinoMab BioScience files board, board committee and management disclosure listPUBT·Jul 3 at 11:25 AM03681+0.88%
SinoMab Bioscience Clarifies Board Structure and Committee RolesTip Ranks·Jun 12 at 03:10 PM03681+0.88%
